Autolus named as one of The Guardian's six firms to watch in 2023

UCLB spinout Autolus Therapeutics has been named in The Guardian’s ‘Six Firms to Watch in 2023’.

Spun out from University College London in 2014, the business develops programmed T cell therapies: also known as living medicines, they re-engineer patients’ immune systems to recognise and attack cancer.

Four years ago, Autolus floated on Nasdaq, raising $160m, and has just raised a further $150m (£125m) from investors, including the British life science investment firm Syncona. It also counts Blackstone Life Sciences among its backers, which has invested up to $250m in one of the largest ever private financings of a UK biotech company.

Read the full story from The Guardian.